Eight domains.
One architecture.
Eight analytical domains run on a single validator-governed deterministic pathway. Each shares the same structured output, descriptor lineage, separated clinical and research layers, and reproducible longitudinal comparison. The domains are facets of one architecture, not separate products.
A single pathway across eight domains.
The map below is not a product roadmap. Each domain applies the same validator-governed pathway — identical deterministic structuring, descriptor lineage, and clinical–research separation — to a different clinical or research territory. Select a domain to open its page.
All eight domains share one architectural spine. Domain 08 — Clinical Trial Imaging — is a cross-cutting use case rather than a specialty.
Domain status.
All eight domains are active and demonstrated. The table groups them by type: seven specialty domains and one cross-cutting capability that runs across them.
Active and demonstrated; partnership-relevant.
An architecture-level capability extending across every domain above.
Domains in detail.
01
Inflammatory & Autoimmune Arthritis
Demonstrated
Active
Rheumatoid arthritis, psoriatic arthritis, and axial/peripheral spondyloarthritis. Structured longitudinal tracking, phenotype-level differentiation, and treatment-response correlation across timepoints. Output separates inflammatory progression from degenerative change and yields research-grade endpoints suitable for clinical trials.
02
Degenerative & Mechanical Disease
Demonstrated
Active
Osteoarthritis, degenerative disc disease, spondylosis, DISH, and mechanical joint deterioration. Projection-normalized structural scoring with compartmental analysis. Deterministic separation of inflammatory from degenerative patterns supports cleaner cohort stratification and more defensible endpoints in OA trials.
03
Spine & Neuroradiology
Demonstrated
Active
Cervical, thoracic, and lumbar spine, with structured cross-modality concordance between plain radiographs and MRI. Instability, canal, and foraminal assessment within a reproducible framework; imaging findings correlated with functional indicators. Applicable to surgical planning, clinical trials, and structured documentation.
04
Metabolic Bone Disease
Demonstrated
Active
Mineralization analytics from plain radiographs — a reproducible complementary layer to densitometry, not a replacement. Osteoporosis indicators, metabolic pattern recognition, DXA–radiograph concordance, Paget’s disease, and therapy-response tracking from imaging already acquired in routine practice.
05
Pediatric Musculoskeletal Imaging
Demonstrated
Active
Developmental normalization for pediatric studies: age-indexed variance modeling, growth-trajectory analysis, and pediatric-specific structural assessment. Addresses a common gap, where pediatric imaging is read without formal developmental adjustment.
06
Orthopedics & Trauma
Demonstrated
Active
Fracture characterization, post-surgical structural assessment, alignment analysis, hardware evaluation, and biomechanical load inference within the same validator-governed framework. Reproducible, quantifiable output for post-operative surveillance and longitudinal outcome tracking.
07
Cross-Modality & Quantitative Research
Demonstrated
Active
The research layer beneath clinical output. Multi-modal integration across X-ray, MRI, CT, and DXA; quantitative extraction, phenotype-level pattern analysis, and longitudinal drift computation. Deterministic, traceable, and exportable, with full descriptor lineage. Turns imaging into a governed quantitative data source for academic researchers, biostatisticians, and translational teams.
One use case across all domains.
Domain 08 is not parallel to the others. It draws on every domain above to produce harmonized, audit-ready output for multi-center imaging trials.
Clinical Trial Imaging
Harmonized multi-site endpoints, reproducible longitudinal scoring, trial-compatible structured export, and cross-reader consistency verification. Variability is addressed as a structural property of the validator-governed pathway rather than as a downstream calibration step, producing output built to withstand regulatory review.
View full domain page →What is public, and what is not.
Every domain runs on the same unified validator-governed architecture, with deterministic lineage, clinical–research layer separation, and full audit traceability. The architecture, classification framework, and output formats are described publicly. The validator chain, descriptor formulas, and operator-level mechanics remain proprietary and are disclosed only under partnership and NDA.
The public surface is sufficient to evaluate fit; the proprietary layer is what makes the architecture defensible.
Engagement channels.
Trial-compatible extraction
Harmonized multi-site endpoints, reproducible longitudinal scoring, and structured export for multi-center imaging trials.
Open partnership inquiry →Research analytic addendum
Quantitative extraction, methodology, and research-tier output for biostatisticians and translational teams.
Open research dialogue →Architectural overview
Architectural review, defensibility analysis, and partnership-level discussion under NDA.
Request architectural brief →All inquiries route through a single secure channel.
contact_us@rheumaview.comPublic materials describe categories, architecture, and domain breadth. Implementation details — validator rules, descriptor formulas, operator mechanics — remain proprietary. Patent-pending positioning. RheumaView™ is intended for use by licensed medical professionals and qualified research environments. Not a patient-facing diagnostic tool.